CA2417867A1 - Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes - Google Patents
Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes Download PDFInfo
- Publication number
- CA2417867A1 CA2417867A1 CA002417867A CA2417867A CA2417867A1 CA 2417867 A1 CA2417867 A1 CA 2417867A1 CA 002417867 A CA002417867 A CA 002417867A CA 2417867 A CA2417867 A CA 2417867A CA 2417867 A1 CA2417867 A1 CA 2417867A1
- Authority
- CA
- Canada
- Prior art keywords
- cascade
- effective amount
- comprises administering
- treat
- sodium hyaluronate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 42
- 150000001720 carbohydrates Chemical class 0.000 title claims abstract 23
- 201000010099 disease Diseases 0.000 title claims abstract 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 18
- 235000014633 carbohydrates Nutrition 0.000 title claims 20
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 18
- 230000007815 allergy Effects 0.000 claims abstract 15
- 230000001394 metastastic effect Effects 0.000 claims abstract 12
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract 12
- 230000005784 autoimmunity Effects 0.000 claims abstract 10
- 229920001542 oligosaccharide Polymers 0.000 claims abstract 8
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract 8
- 239000004480 active ingredient Substances 0.000 claims abstract 6
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract 4
- 150000004676 glycans Chemical class 0.000 claims abstract 4
- 229920001282 polysaccharide Polymers 0.000 claims abstract 4
- 239000005017 polysaccharide Substances 0.000 claims abstract 4
- 239000002537 cosmetic Substances 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 210000004369 blood Anatomy 0.000 claims abstract 2
- 239000008280 blood Substances 0.000 claims abstract 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 18
- 229940010747 sodium hyaluronate Drugs 0.000 claims 18
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 10
- 210000004204 blood vessel Anatomy 0.000 claims 7
- 108020003175 receptors Proteins 0.000 claims 7
- 102000005962 receptors Human genes 0.000 claims 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 6
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 6
- 229940059329 chondroitin sulfate Drugs 0.000 claims 6
- 210000000265 leukocyte Anatomy 0.000 claims 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 206010017533 Fungal infection Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000007246 mechanism Effects 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000006373 Bell palsy Diseases 0.000 claims 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 108010003425 hyaluronan-mediated motility receptor Proteins 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000004899 motility Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 230000005808 skin problem Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 210000001738 temporomandibular joint Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010049589 Afterbirth pain Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims 1
- 206010022714 Intestinal ulcer Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 102000016979 Other receptors Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 235000014220 Rhus chinensis Nutrition 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 102000003800 Selectins Human genes 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 241000159241 Toxicodendron Species 0.000 claims 1
- 241000159243 Toxicodendron radicans Species 0.000 claims 1
- 241000871311 Toxicodendron vernix Species 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 208000019669 cervical disc degenerative disease Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000002925 dental caries Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 210000004905 finger nail Anatomy 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000001032 spinal nerve Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un procédé de prévention et de traitement de maladies et d'états pathologiques associés à des allergies, à l'auto-immunité, à la cascade d'adhérences ou aux cascades métastatiques ou coronaires, ce qui consiste à administrer (i) au moins un glucide complexe en tant qu'ingrédient actif unique ou (ii) au moins une composition pharmaceutique contenant en tant qu'ingrédient actif une quantité efficace sur le plan pharmacologique d'au moins un glucide complexe de pureté limitée ou de grade cosmétique sélectionné dans le groupe constitué par des oligosaccharides, des oligosaccharides sialylés, des polysaccharides et des glucosaminoglycanes, ainsi qu'une quantité efficace d'au moins un véhicule transdermique, ou pouvant traverser la muqueuse, et suffisante pour introduire dans la circulation sanguine le glucide complexe.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22204600P | 2000-07-31 | 2000-07-31 | |
| US60/222,046 | 2000-07-31 | ||
| PCT/US2001/041473 WO2002009728A1 (fr) | 2000-07-31 | 2001-07-31 | Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2417867A1 true CA2417867A1 (fr) | 2002-02-27 |
| CA2417867C CA2417867C (fr) | 2012-09-11 |
Family
ID=22830558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2417867A Expired - Lifetime CA2417867C (fr) | 2000-07-31 | 2001-07-31 | Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1311276A4 (fr) |
| AU (2) | AU8136801A (fr) |
| CA (1) | CA2417867C (fr) |
| NZ (2) | NZ524076A (fr) |
| WO (1) | WO2002009728A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021113986A1 (fr) * | 2019-12-13 | 2021-06-17 | Folium Labs Inc. | Complexes comprenant un polymère de glucide et un principe actif et leurs procédés de préparation |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916565A (en) | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| WO2002060471A2 (fr) * | 2001-01-30 | 2002-08-08 | Ich Productions Limited | Ligands des proteines tyrosine phosphatases de type recepteur |
| ITMI20021866A1 (it) * | 2002-08-30 | 2004-02-29 | Luigi Allegra | Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee. |
| US7060691B2 (en) * | 2002-10-10 | 2006-06-13 | Giuseppe Petrigni | Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases |
| US8519008B2 (en) | 2003-01-22 | 2013-08-27 | Purina Animal Nutrition Llc | Method and composition for improving the health of young monogastric mammals |
| US20040161476A1 (en) * | 2003-02-19 | 2004-08-19 | Hahn Sungtack Samuel | Cystitis treatment with high dose chondroitin sulfate |
| US7511026B2 (en) | 2003-03-25 | 2009-03-31 | Seikagaku Corporation | Therapeutic agent for nerve damage |
| US20070225484A1 (en) * | 2006-03-25 | 2007-09-27 | Framroze Bomi P | Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells |
| MX2008014403A (es) * | 2006-05-11 | 2009-03-23 | Sandra Gobbo | Mezclas binarias del acido hialuronico y su uso terapeutico. |
| ITMI20061030A1 (it) | 2006-05-26 | 2007-11-27 | Altergon Sa | Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica |
| DE102006060953A1 (de) * | 2006-12-12 | 2008-08-07 | Farco-Pharma Gmbh | Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes |
| ES2405314T3 (es) * | 2008-05-13 | 2013-05-30 | Apharm S.R.L. | Composiciones y uso oral de glicosaminoglicanos |
| US9241953B2 (en) | 2008-05-13 | 2016-01-26 | Apharm S.R.L. | Glycosaminoglycan oral use and compositions |
| TWI516269B (zh) * | 2009-08-14 | 2016-01-11 | 禾伸堂生技股份有限公司 | 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物 |
| TWI383796B (zh) * | 2009-08-14 | 2013-02-01 | Holy Stone Healthcare Co Ltd | Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer |
| FR2959415B1 (fr) * | 2010-04-30 | 2012-07-13 | Ayawane | Composition dermatologique a base d'huile d'argan et d'acide hyaluronique. |
| FI20115631A0 (fi) | 2011-06-21 | 2011-06-21 | Turun Yliopisto | Immunostimulatoriset yhdisteet ja niiden käyttö |
| ITMI20130117A1 (it) * | 2013-01-25 | 2014-07-26 | Gnosis Spa | Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato |
| EP3479830B1 (fr) * | 2016-04-25 | 2024-09-11 | College of Animal Science & Technology, Qingdao Agriculture University | Utilisation d'un fragment d'acide hyaluronique à petites molécules |
| CN108721320A (zh) * | 2017-04-24 | 2018-11-02 | 惠觅宙 | 小分子透明质酸片段的应用 |
| CN107303271A (zh) * | 2016-04-25 | 2017-10-31 | 惠觅宙 | 一种含有小分子透明质酸的注射液及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005517A1 (fr) * | 1986-03-14 | 1987-09-24 | Bio-Technology General Corp. | Sels de metaux lourds de l'acide hyaluronique utiles en tant qu'agents antimicrobiens |
| US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
| EP0254845A3 (fr) * | 1986-06-10 | 1989-04-19 | Lescarden Inc. | Stimulation d'immunité avec le chondroitine sulfate |
| WO1988001280A1 (fr) * | 1986-08-21 | 1988-02-25 | Board Of Regents, The University Of Texas System | Derives de glycosaminoglycane et leur utilisation comme inhibiteurs de l'invasion tumorale ou proliferation metastatique |
| WO1991013624A1 (fr) * | 1990-03-05 | 1991-09-19 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Glycosaminoglycans sulfates endogenes induits par suramine, utilises comme agents anti-cancereux chez l'homme |
| DE69120933T2 (de) * | 1991-04-18 | 1997-01-16 | Baldacci Lab Spa | Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen |
| AU3159595A (en) * | 1994-08-30 | 1996-03-22 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
| CA2175282A1 (fr) * | 1996-04-29 | 1997-10-30 | Rudolf Edgar Falk | Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer |
| US5929050A (en) * | 1998-02-27 | 1999-07-27 | Petito; George D. | Chondroitin sulfate composition and method for wound treatment |
| IT1301994B1 (it) * | 1998-08-05 | 2000-07-20 | Jasper Ltd Liability Co | Derivati dell'acido ialuronico. |
| US6083933A (en) * | 1999-04-19 | 2000-07-04 | Stellar International Inc. | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution |
-
2001
- 2001-07-31 NZ NZ524076A patent/NZ524076A/en unknown
- 2001-07-31 AU AU8136801A patent/AU8136801A/xx active Pending
- 2001-07-31 WO PCT/US2001/041473 patent/WO2002009728A1/fr active IP Right Grant
- 2001-07-31 CA CA2417867A patent/CA2417867C/fr not_active Expired - Lifetime
- 2001-07-31 AU AU2001281368A patent/AU2001281368B2/en not_active Ceased
- 2001-07-31 NZ NZ53307801A patent/NZ533078A/en not_active IP Right Cessation
- 2001-07-31 EP EP01959852A patent/EP1311276A4/fr not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021113986A1 (fr) * | 2019-12-13 | 2021-06-17 | Folium Labs Inc. | Complexes comprenant un polymère de glucide et un principe actif et leurs procédés de préparation |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ533078A (en) | 2006-11-30 |
| EP1311276A4 (fr) | 2007-09-12 |
| CA2417867C (fr) | 2012-09-11 |
| AU2001281368B2 (en) | 2005-07-28 |
| AU8136801A (en) | 2002-02-13 |
| NZ524076A (en) | 2004-07-30 |
| EP1311276A1 (fr) | 2003-05-21 |
| WO2002009728A1 (fr) | 2002-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2417867A1 (fr) | Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes | |
| SK459890A3 (en) | USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT | |
| Shelley et al. | Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis | |
| DE69825279T2 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| WO2003092597A3 (fr) | Anticorps a liaison specifique avec la chimiokine beta-4 (ck-b4) | |
| EP0363402B1 (fr) | Composition d'acide cyclopolygalacturonique et son utilisation | |
| JPH11335288A (ja) | アレルギー性疾患の予防または治療薬 | |
| EP2229947A3 (fr) | Polymères biocompatibles pour une composition médicale | |
| US7132412B2 (en) | Treatment of skin diseases using a pharmaceutical preparation in colloidal form | |
| CN115282105A (zh) | 一种婴童护肤组合物及其制备方法 | |
| CN1067245C (zh) | N－乙酰－d－氨基葡萄糖在制备治疗呼吸道疾病的药物中的应用 | |
| Baixauli et al. | Percutaneous treatment of acute soft tissue lesions with naproxen gel and ketoprofen gel | |
| RU2005488C1 (ru) | Средство для лечения болезней соединительной ткани | |
| DE19632840A1 (de) | Vitamin A-haltige Zusammensetzung | |
| CN1287846C (zh) | 抗炎止痒洗剂 | |
| CN1274596A (zh) | 复方蜂毒搽剂及其制备方法 | |
| US20030092682A1 (en) | Use of doxycycline for treatment of certain skin and mouth ailments | |
| Ochsner et al. | Roentgen therapy for painful conditions of the bones and joints | |
| RU2749369C2 (ru) | Способ лечения обширных поверхностных повреждений кожи | |
| CN110709088A (zh) | 葡糖胺基葡聚糖产生促进剂及葡糖胺基葡聚糖产生促进用组合物 | |
| SU1680188A1 (ru) | Способ лечени синдром зап стного канала | |
| CN1272035C (zh) | 一种治疗口腔溃疡的中药制剂 | |
| CN1298373C (zh) | 治疗高血压的中药 | |
| CN1166374C (zh) | 一种治疗中风后遗症偏瘫的药物 | |
| CN1278673C (zh) | 黏膜消炎用干粉喷剂及生产方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210803 |